Designed for Better Patient Outcomes
See how the Ranger Drug Coated Balloon leverages proven
and safe Boston Scientific technologies for the SFA and help
improve patients’ lives.
Director, Research and Development - Boston Scientific Corporation
Ranger is a next generation DCB supported by Level 1 evidence.
Ranger is available on the 0.018" Sterling balloon catheter platform which contributes to its ease of use and deliverability. Ranger has a proprietary loading tool to ensure coating integrity. Ranger has one of the broadest size matrix including new 120, 150 and 200 mm lengths
TRANSPAX™ COATING TECHNOLOGY
Ranger's TransPax™ Techonolgy consists of Paclitaxel + Citrate ester (Excipient) for best in class coating integrity, making Ranger more efficient DCB. Ranger is able to use approximately half the drug load that is used in IN.PACT DCB
Eluvia and Ranger are the lowest drug dose density devices among all peripheral paclitaxel-based technologies.
Data from Eluvia, Lutonix, Stellarex, Ranger, Zilver PTX and IN.PACT DFUs.
Ranger uses a unique combination of low drug dose with a proprietary excipient for efficient, local drug-delivery
*Comparitive tissue levels up to 60 days of a standard dose paclitaxel-coated balloon (PCB) (In.Pact) versus a lower-dose balloon (Ranger) in the superficial femoral artery territory of the swine. Dashed line represents the comparitive data with the Lutonix PCB (11). DCB = drug-coated balloon.
**JACC Gongora C. et. al. , Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. JACC Cardiovasc Interv. 2015 Jul;8(8):1115-23 Preclinical results may not necessarily be indicative of clinical performance.
Total Drug Lost to Tracking, Inflation & Deflation
*Bench Testing performed by Boston Scientific. Results not necessarily indicative of clinical performance. Data on File Boston Scientific.
DCB Design & platform
The Ranger Drug Coated balloon is indicated for Percutaneous Transluminal Angioplasty (PTA) in the peripheral vasculature. It has been designed to provide consistent and predictable drug delivery through efficient drug transfer, and a strong coating integrity
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.